乌司奴单抗治疗溃疡性结肠炎的研究进展  

Research Advances of Ustekinumab in the Treatment of Ulcerative Colitis

作　　者：袁明聪 郭海嬿 王重惠 马继敏 王学昌 

机构地区：[1]大理大学药学院,云南 大理 [2]安宁市第一人民医院药学部,云南 昆明

出　　处：《临床医学进展》2025年第1期523-529,共7页Advances in Clinical Medicine

摘　　要：溃疡性结肠炎(UC)是一种发病机制不明的慢性炎症性肠病,近年来生物制剂已被用于治疗UC,其疗效甚至优于传统的治疗药物。乌司奴单抗是一种抗白介素(IL)-12/23的新型生物制剂,为传统药物或其他生物制剂治疗失败的UC患者提供了新选择。本文就乌司奴单抗对UC的作用机制、临床疗效和安全性作一综述。结果表明乌司奴单抗通过与IL-12和IL-23共有的p40亚基结合,从而抑制肠道炎症,缓解UC患者的症状。并且乌司奴单抗在临床上也显示出较好的疗效与安全性,其安全性与安慰剂大致相当。由于目前暂未见其在我国用于UC,未来需进一步研究乌司奴单抗在我国UC患者中的疗效和安全性。Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown pathogenesis. In recent years, biologics have been used to treat UC with even better efficacy than traditional therapeutic drugs. Ustekinumab, a novel biologic agent against interleukin-12/23 (IL-12/23), offers a new option for UC patients who have failed treatment with conventional drugs or other biologics. This article reviews the mechanism of action, clinical efficacy and safety of ustekinumab in ulcerative colitis. The results suggest that ustekinumab alleviates the symptoms of UC patients by binding to the p40 subunit shared by IL-12 and IL-23, thereby inhibiting intestinal inflammation. And ustekinumab has also shown good efficacy and safety in clinical practice, with a safety profile roughly comparable to that of placebo. As its use for UC in China is not currently seen, further studies on the efficacy and safety of ustekinumab in Chinese patients are needed in the future.

关 键 词：溃疡性结肠炎 乌司奴单抗 IL-12/IL-23 临床疗效 

分 类 号：R57[医药卫生—消化系统]